IDEXX Laboratories Inc logo

IDEXX Laboratories Inc(IDXX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 19 days
PROFIT SINCE LAST BUY
+26.22% ▲
LAST CLOSE
$704.23
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IDXX

11/13/2026: IDXX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

IDEXX Laboratories Inc is a leading global provider of diagnostic and information technology solutions for companion animals, livestock, and water quality testing. The company's primary strengths stem from an integrated ecosystem of proprietary in-clinic instruments, reference labs, and software that drives high customer retention and recurring consumable revenues. Its main growth opportunity lies in expanding international diagnostic testing penetration and integrating advanced AI workflow solutions like CoVet. However, key risks include elevated valuation multiples, reliance on discretionary pet healthcare spending, and intense competition from well-capitalized rivals. The stock best suits growth-oriented investors willing to monitor execution risks and valuation sensitivity.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitIDEXX consistently delivers double-digit revenue and earnings growth driven by secular tailwinds in pet healthcare.
Momentum investorStrong fit while signal remains positiveThe stock often exhibits strong multi-year momentum backed by consistent earnings beats and robust organic growth trends.
Value investorWeak fitThe company trades at a premium valuation multiple that reflects its high quality and growth profile.
Dividend investorWeak fitIDEXX does not pay a regular cash dividend, focusing instead on capital reinvestment and share repurchases.
Low-risk investorMixed fitWhile the business model is resilient and high quality, premium valuation multiples expose the stock to price volatility during market pullbacks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highHigh growth expectations can amplify stock price swings during broader market corrections.
Valuation riskHighTrading at elevated price-to-earnings multiples leaves the stock sensitive to any unexpected deceleration in growth.
Competition risk (Mars Petcare / Antech and Zoetis)Medium / highAggressive moves by well-funded competitors could pressure market share in reference labs and diagnostics.
Business qualityStrongHigh recurring revenue streams and entrenched customer relationships underpin exceptional franchise quality.
Dividend incomeLow / noneIncome-focused investors will find no regular dividend distributions.
Execution riskMediumSustaining high organic growth requires continuous successful execution of new product launches and global sales initiatives.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 55.48B USD
Price to earnings Ratio 47.45
1Y Target Price 717.17
Price to earnings Ratio 47.45
1Y Target Price 717.17
Volume (30-day avg) 657.9K shares
Beta 1.54
52 Weeks Range 500.61 - 769.98
Updated Date 11/15/2026
52 Weeks Range 500.61 - 769.98
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 14.84

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit 59.87%
Avg. Invested days 41
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IDXX receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum, and limited analyst upside.

Company Fundamentals

★★★★★
IDXX has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+19.3%) and strong cash generation (FCF margin 24.5%) are partially offset by very low insider ownership of 0.68%.

Financial Health Rating

★★★★★
IDXX's financial health is supported by strong cash strength, including free-cash-flow generation of $1.1B (24.5% of revenue). Liquidity is moderate (3 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IDXX's strongest growth driver at +32.0% FY2025 versus FY2024 (solid, 4 stars). Revenue growth (+10.4%, solid) and earnings growth (+19.3%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 94.6% and approximately 99.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.68%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 10.37%
Vanguard Capital Management, LLC 6.54%
Vanguard Portfolio Management, LLC 4.95%
State Street Corp 4.76%
Amvescap Plc. 4.58%

Unit Economics (Per $1K Revenue)

★★★★★
IDXX generates approximately $618 of gross profit, $316 of operating income, and $245 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 19.99%

Quantitative Style Profile

★★★★★
IDXX has a high-quality, large-cap, liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Quality TiltHigh VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Companion Animal Group (CAG) Diagnostics Recurring RevenueConsumables for in-clinic analyzers, rapid test kits (SNAP), and reference laboratory diagnostic testing services.This is the primary growth engine, generating sticky, recurring revenue every time a vet runs a test.
Premium Instrument SystemsSales and placements of in-clinic diagnostic equipment such as Catalyst One, ProCyte Dx, and inVue Dx.Placing analyzers in clinics creates a captive installed base that subsequently buys high-margin consumables.
Water Quality ProductsMicrobiological testing kits and instruments for municipal and industrial water safety compliance.Provides a steady, defensive stream of non-veterinary revenue tied to regulatory safety testing standards.
Veterinary Software and ServicesCloud-based practice management software (ezyVet) and AI-enabled scribe tools (CoVet).Deepens clinic workflow integration, increasing customer retention and ecosystem lock-in.
Geographic ExposureInternational sales across Europe, Asia-Pacific, and the Americas alongside North America.Offers global diversification, though foreign exchange movements can impact reported results.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-02
When Before Market
Estimate 3.71
Actual 3.98

Profitability

Profit Margin 25.36%
Operating Margin (TTM) 32.5%

Management Effectiveness

Return on Assets (TTM) 26.7%
Return on Equity (TTM) 68.93%

Valuation

Trailing PE 47.45
Forward PE 41.49
Enterprise Value 56.26B
Price to Sales(TTM) 11.9
Enterprise Value 56.26B
Price to Sales(TTM) 11.9
Enterprise Value to Revenue 12.07
Enterprise Value to EBITDA 33.66
Shares Outstanding 78.79M
Shares Floating 78.51M
Shares Outstanding 78.79M
Shares Floating 78.51M
Percent Insiders 0.68
Percent Institutions 94.64

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.